SPACInsider Logo
Lakeshore I (LAAA) Secures $30M for ProSomnus Deal
by Marlena Haddad on 2022-08-26 at 5:18pm

Lakeshore Acquisition I Corp. (NASDAQ:LAAA) has signed definitive agreements for $30 million in convertible notes for its combination with medical device company ProSomnus.

The recent commitment of debt financing comes from institutional investors led by funds affiliated with or managed by Cohanzick Management, LLC and CrossingBridge Advisors, LLC, but the closing of the notes are conditioned upon the closing of the business combination prior to December 10, 2022.

The $30 million debt facility, which is being issued to various institutional parties, is comprised of two tranches:  $15 million of senior secured convertible notes and $15 million of junior secured convertible notes with maturities of 36 months and 40 months, respectively.

Following the issuance, within 12 months, the debt will be eligible for secondary trading. The senior debt has an initial conversion price of $13.00, which is to be reset at 5% premium to market price six and twelve months after closing, subject to a floor while the subordinated debt has an initial conversion price of $11.50, to be reset to a 5% premium to the market price six and twelve months after close and subject to a floor.

The financing plays an important role in closing Lakeshore’s business combination with ProSomnus. With Lakeshore bringing in $55 million into the deal from its current trust, the $30 million in convertible notes will help strengthen the company’s balance sheet. The parties disclosed the term sheet for the senior and junior notes at deal announcement, but at that time the funding was not definite as it was subject to today’s signing of the definitive convertible debt agreements. Lakeshore must maintain at least $40 million in cash and cash equivalents available after closing.

Lakeshore and ProSomnus disclosed that they expect to use the proceeds of the facility to fund multiple strategic growth initiatives such as continued growth of the sales team to expand the company’s international presence. ProSomnus also plans to complete the development of its next-generation Oral Appliance Therapy, which features sensors that allow physicians to monitor their patients during critical hours.  Other initiatives for ProSomnus include investments in manufacturing techniques, raising efforts of public awareness of Obstructive Sleep Apnea, and the value-added features of the company’s new therapy devices.

The combined company is expected to change its name to ProSomnus, Inc. and its class A common stock is expected to be traded on the Nasdaq Capital Market under the symbol “OSA”.

The parties initially announced the $168 million combination a few months ago on May 10. Pleasanton, California-based ProSomnus customizes oral appliance therapy devices to treat obstructive sleep apnea. Precision oral appliance therapy is a new option for treating obstructive sleep apnea, where each ProSomnus device is personalized and digitally manufactured to match the anatomy and treatment plan for each patient.

 

 

Recent Posts
by Kristi Marvin on 2023-01-28 at 1:59pm

Terms Tracker for the Week Ending January 27, 2022 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. We’re coming up on the end of January, the first month of the year, and to-date no new S-1s have been filed. Additionally, the number...

by Marlena Haddad on 2023-01-27 at 11:34am

  Below is a daily summary of links to the latest SPAC news and rumors gathered across the web.  Latest SPAC News: Circle spokesperson denies blaming SEC for failed deal, BuzzFeed CEO says AI-powered content will be part of core business, and FaZe Clan faces possible delisting Circle Spokesperson Denies Blaming SEC for Failed $9 Billion Deal...

by Nicholas Alan Clayton on 2023-01-27 at 10:00am

Health Sciences 2 (NASDAQ:HSAQ) announced that it closed its combination with Orchestra BioMed on January 26. HSAQ ahead of its vote pre-announced redemption figures of 1,597,888 shares equating to 67.7% redemptions, however, that’s still subject to change.  However, today it was noted that Orchestra BioMed is to receive $70 million in gross proceeds including $20...

by Kristi Marvin on 2023-01-27 at 7:33am

Carbon capture technology has long been talked about, and it is finally in operation with LanzaTech among the pioneers. Its plants are turning potential emissions into clothing, household goods and sustainable fuels. SPAC cash is now also an accelerant in this new process as the company announced a $1.7 billion combination with AMCI II last March. This week, we caught up with...

by Nicholas Alan Clayton on 2023-01-27 at 7:30am

In this series we’ll be examining successful SPAC deals from the past both in the terms and circumstances of their de-SPAC processes and how they have weathered the storms that have followed after their public listings with research from SPACInsider contributor Anthony Sozzi. Thirty months does not sound like that long, but it’s been a...

Privacy Policy|Terms Of Use
Copyright © 2022 SPACInsider, Inc. All Rights Reserved